Tags

Type your tag names separated by a space and hit enter

Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Medscape J Med. 2008 Mar 11; 10(3):60.MJ

Abstract

BACKGROUND AND PURPOSE

Cyclooxygenase (COX) is an angiogenic factor that is strongly related to inflammatory diseases and the development of cancer and metastasis in several cancers. It is overexpressed in a variety of premalignant and malignant conditions, including urinary bladder cancer. Our aim was to investigate and compare the expression of COX-2 enzyme in patients with bladder cancer, chronic cystitis, and normal bladder tissue. The results were correlated to the classic prognostic factors, mainly tumor stage and grade, in a trial to determine the prognostic significance of COX-2 marker.

MATERIALS AND METHODS

Seventy-five bladder samples were taken, including 50 cases with bladder cancer (31 were schistosomal-associated and 19 non-schistosomal-associated), 20 samples from cases with chronic cystitis (7 were nonschistosomal and 13 were schistosomal cystitis), and 5 samples from normal bladder tissue taken as control. The specimens were stained by streptavidin-biotin immunohistochemistry protocol, with COX-2 monoclonal antibody.

RESULTS

Although no notable expression of COX-2 was observed in the normal bladder, it was slightly expressed in chronic cystitis especially in areas of dysplasia and squamous metaplasia, whereas there was a significant increase in COX-2 (P < .001) with moderate-to-strong granular cytoplasmic expression in all malignant histologic types. The COX-2 reactivity was higher in transitional cell carcinoma (TCC) than in squamous cell carcinoma (SqCC) (P < .01). COX-2 expression was significantly higher in schistosomal-associated TCC than in non-schistosomal-associated TCC (P < .01). There was a statistically significant positive correlation between COX-2 expression and tumor grade (P = .0052). COX-2 expression was significantly higher in grade 3 bladder TCC than in grades 1 and 2 bladder TCC (P < .05, P < .01). A correlation between COX-2 expression and progression of bladder TCC also was observed (P = .001). There was a significant difference in COX-2 expression level between the bladder TCCs at different clinical stages (P < .01).

CONCLUSION

COX-2 is overexpressed in schistosomal-associated bladder cancer. COX-2 may be of significance to the development and proliferation of bladder TCC, consistent with a potential role for COX-2 inhibitors in the prevention and management of this disease.

Authors+Show Affiliations

Theodor Bilharz Research Institute, Giza, Egypt. drolfathammam@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18449376

Citation

Hammam, Olfat Ali, et al. "Possible Role of Cyclooxygenase-2 in Schistosomal and Non-schistosomal-associated Bladder Cancer." Medscape Journal of Medicine, vol. 10, no. 3, 2008, p. 60.
Hammam OA, Aziz AA, Roshdy MS, et al. Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. Medscape J Med. 2008;10(3):60.
Hammam, O. A., Aziz, A. A., Roshdy, M. S., & Abdel Hadi, A. M. (2008). Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. Medscape Journal of Medicine, 10(3), 60.
Hammam OA, et al. Possible Role of Cyclooxygenase-2 in Schistosomal and Non-schistosomal-associated Bladder Cancer. Medscape J Med. 2008 Mar 11;10(3):60. PubMed PMID: 18449376.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. AU - Hammam,Olfat Ali, AU - Aziz,Ahmed A, AU - Roshdy,Mamdouh S, AU - Abdel Hadi,Ahmed M, Y1 - 2008/03/11/ PY - 2008/5/2/pubmed PY - 2008/6/5/medline PY - 2008/5/2/entrez SP - 60 EP - 60 JF - Medscape journal of medicine JO - Medscape J Med VL - 10 IS - 3 N2 - BACKGROUND AND PURPOSE: Cyclooxygenase (COX) is an angiogenic factor that is strongly related to inflammatory diseases and the development of cancer and metastasis in several cancers. It is overexpressed in a variety of premalignant and malignant conditions, including urinary bladder cancer. Our aim was to investigate and compare the expression of COX-2 enzyme in patients with bladder cancer, chronic cystitis, and normal bladder tissue. The results were correlated to the classic prognostic factors, mainly tumor stage and grade, in a trial to determine the prognostic significance of COX-2 marker. MATERIALS AND METHODS: Seventy-five bladder samples were taken, including 50 cases with bladder cancer (31 were schistosomal-associated and 19 non-schistosomal-associated), 20 samples from cases with chronic cystitis (7 were nonschistosomal and 13 were schistosomal cystitis), and 5 samples from normal bladder tissue taken as control. The specimens were stained by streptavidin-biotin immunohistochemistry protocol, with COX-2 monoclonal antibody. RESULTS: Although no notable expression of COX-2 was observed in the normal bladder, it was slightly expressed in chronic cystitis especially in areas of dysplasia and squamous metaplasia, whereas there was a significant increase in COX-2 (P < .001) with moderate-to-strong granular cytoplasmic expression in all malignant histologic types. The COX-2 reactivity was higher in transitional cell carcinoma (TCC) than in squamous cell carcinoma (SqCC) (P < .01). COX-2 expression was significantly higher in schistosomal-associated TCC than in non-schistosomal-associated TCC (P < .01). There was a statistically significant positive correlation between COX-2 expression and tumor grade (P = .0052). COX-2 expression was significantly higher in grade 3 bladder TCC than in grades 1 and 2 bladder TCC (P < .05, P < .01). A correlation between COX-2 expression and progression of bladder TCC also was observed (P = .001). There was a significant difference in COX-2 expression level between the bladder TCCs at different clinical stages (P < .01). CONCLUSION: COX-2 is overexpressed in schistosomal-associated bladder cancer. COX-2 may be of significance to the development and proliferation of bladder TCC, consistent with a potential role for COX-2 inhibitors in the prevention and management of this disease. SN - 1934-1997 UR - https://www.unboundmedicine.com/medline/citation/18449376/Possible_role_of_cyclooxygenase_2_in_schistosomal_and_non_schistosomal_associated_bladder_cancer_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18449376/ DB - PRIME DP - Unbound Medicine ER -